Renal Protective Effects of Circulating Angiopoietin-like-4

循环血管生成素样 4 的肾脏保护作用

基本信息

  • 批准号:
    8816097
  • 负责人:
  • 金额:
    $ 31.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-03-10 至 2019-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Reducing proteinuria slows the progression of chronic kidney disease. The current standard of care is to block of the renin - angiotensin system at various levels to reduce proteinuria. However, reduction of proteinuria is often incomplete, since other pathways involved in the pathogenesis or modification of proteinuria are not affected by this therapy. The long term goal of the PI's lab is to develop novel mechanism - based therapeutic agents that will reduce proteinuria and reduce the progression of chronic kidney disease due to glomerular disorders. Reducing the progression of chronic kidney disease to end stage kidney disease will have a major positive social and financial impact in the United States and worldwide. The PI's laboratory has discovered a major role of the circulating glycoprotein Angiopoietin-like-4 (Angptl4) in human and experimental nephrotic syndrome. Studies conducted by his team show that circulating Angptl4 is the first molecular link between proteinuria, hypoalbuminemia and hypertriglyceridemia, three major components of nephrotic syndrome. In glomerular disease, increased Angptl4 secretion from skeletal muscle, heart, liver and adipose tissue occurs when proteinuria becomes moderate to severe (in the human context, when it reaches nephrotic range). Circulating Angptl4 reduces proteinuria by binding to glomerular endothelial ?v?5 integrin, while also inducing hypertriglyceridemia by inhibiting the activity of endothelium bound lipoprotein lipase. Further, it appears that this multi-organ upregulation of Angptl4 expression results from an increase in the plasma free fatty acid / albumin ratio. The PI has developed four new mutant forms of human Angptl4 protein that reduce proteinuria in rat models of focal and segmental glomerulosclerosis (FSGS) and diabetic nephropathy without significantly affecting plasma triglyceride levels. In Specific Aim 1, the relationship between elevated plasma free fatty acid / albumin ratio with increased peripheral organ Angptl4 expression in nephrotic syndrome will be investigated further using organ specific PPAR knockout mice. In Specific Aim 2, we will test whether administration of mutant human Angptl4 twice every month, or transgenic expression of rat Angptl4 from adipose tissue can reduce glomerulosclerosis and progression of chronic kidney disease in rats models of FSGS or diabetic nephropathy. In Specific Aim 3, mechanisms by which the interaction of circulating Angptl4 with glomerular endothelial ?v?5 integrin reduces proteinuria will be investigated.
描述(由申请人提供):减少蛋白尿可减缓慢性肾脏疾病的进展。目前的治疗标准是阻断不同水平的肾素-血管紧张素系统以减少蛋白尿。然而,蛋白尿的减少往往是不完全的,因为参与蛋白尿发病或改变的其他途径不受这种治疗的影响。PI实验室的长期目标是开发新的基于机制的治疗药物,以减少蛋白尿和减少肾小球疾病引起的慢性肾脏疾病的进展。减少慢性肾脏疾病的进展到终末期肾脏疾病将对美国和全世界产生重大的积极的社会和经济影响。PI的实验室已经发现了循环糖蛋白血管生成素样4 (Angptl4)在人类和实验性肾病综合征中的主要作用。他的团队进行的研究表明,循环Angptl4是蛋白尿、低白蛋白血症和高甘油三酯血症(肾病综合征的三个主要组成部分)之间的第一个分子联系。在肾小球疾病中,当蛋白尿变为中度至重度时,骨骼肌、心脏、肝脏和脂肪组织的Angptl4分泌增加(在人类环境中,当蛋白尿达到肾病范围时)。循环Angptl4通过与肾小球内皮细胞结合减少蛋白尿。5整合素,同时也通过抑制内皮结合脂蛋白脂肪酶的活性诱导高甘油三酯血症。此外,Angptl4表达的多器官上调似乎是由血浆游离脂肪酸/白蛋白比的增加引起的。PI已经开发了四种新的人类Angptl4蛋白突变形式,可以减少局灶性和节段性肾小球硬化(FSGS)和糖尿病肾病大鼠模型中的蛋白尿,而不会显著影响血浆甘油三酯水平。在Specific Aim 1中,我们将使用器官特异性PPAR敲除小鼠进一步研究肾病综合征患者血浆游离脂肪酸/白蛋白比值升高与周围器官Angptl4表达升高之间的关系。在Specific Aim 2中,我们将测试每月两次给药突变的人类Angptl4,或从脂肪组织中转基因表达大鼠Angptl4是否可以减少FSGS或糖尿病肾病大鼠模型的肾小球硬化和慢性肾病的进展。在Specific Aim 3中,循环Angptl4与肾小球内皮细胞相互作用的机制?整合素减少蛋白尿将被研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sumant Singh Chugh其他文献

Sumant Singh Chugh的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sumant Singh Chugh', 18)}}的其他基金

Covid 19 cytokine storm
Covid 19细胞因子风暴
  • 批准号:
    10279177
  • 财政年份:
    2021
  • 资助金额:
    $ 31.97万
  • 项目类别:
Soluble mediators of relapse
复发的可溶性介质
  • 批准号:
    10396046
  • 财政年份:
    2021
  • 资助金额:
    $ 31.97万
  • 项目类别:
Covid 19 cytokine storm
Covid 19细胞因子风暴
  • 批准号:
    10675520
  • 财政年份:
    2021
  • 资助金额:
    $ 31.97万
  • 项目类别:
Soluble mediators of relapse
复发的可溶性介质
  • 批准号:
    10180409
  • 财政年份:
    2021
  • 资助金额:
    $ 31.97万
  • 项目类别:
Soluble mediators of relapse
复发的可溶性介质
  • 批准号:
    10611346
  • 财政年份:
    2021
  • 资助金额:
    $ 31.97万
  • 项目类别:
ZHX2 in Podocyte Disease
ZHX2 在足细胞疾病中的作用
  • 批准号:
    9765297
  • 财政年份:
    2016
  • 资助金额:
    $ 31.97万
  • 项目类别:
ZHX2 in Podocyte Disease
ZHX2 在足细胞疾病中的作用
  • 批准号:
    10001064
  • 财政年份:
    2016
  • 资助金额:
    $ 31.97万
  • 项目类别:
ZHX2 in Podocyte Disease
ZHX2 在足细胞疾病中的作用
  • 批准号:
    9353800
  • 财政年份:
    2016
  • 资助金额:
    $ 31.97万
  • 项目类别:
Investigation of non-HIV Collapsing Glomerulopathy
非 HIV 塌陷性肾小球病的调查
  • 批准号:
    9750079
  • 财政年份:
    2016
  • 资助金额:
    $ 31.97万
  • 项目类别:
Renal Protective Effects of Circulating Angiopoietin-like-4
循环血管生成素样 4 的肾脏保护作用
  • 批准号:
    9002042
  • 财政年份:
    2014
  • 资助金额:
    $ 31.97万
  • 项目类别:

相似海外基金

RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 31.97万
  • 项目类别:
    Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 31.97万
  • 项目类别:
    Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.97万
  • 项目类别:
    Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.97万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.97万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 31.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 31.97万
  • 项目类别:
    Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
  • 批准号:
    2301846
  • 财政年份:
    2023
  • 资助金额:
    $ 31.97万
  • 项目类别:
    Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 31.97万
  • 项目类别:
    Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
  • 批准号:
    23K16076
  • 财政年份:
    2023
  • 资助金额:
    $ 31.97万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了